Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 3Q

Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 3Q

3Q Revenues: $8.7 billion (+12%)

3Q Earnings: $891.0 million (-40%)

YTD Revenues: $25.2 billion (+15%)

YTD Earnings: $3.2 billion (-24%)

Comments: Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion. Humira sales were $1.7 billion in the quarter, up 13%. Trilipix/TriCor sales were $404 million (+22%). Niaspan sales were up 5% to $225 million. Kaletra sales were down 7% to $328 million and Lupron sales were down 3% to $189 million. Worldwide Diagnostics Sales were $916 million (+1%). Worldwide Vascular Sales were up 19% to $790 million. Worldwide Nutritional Sales were down 2% to $1.4 billion. Earnings in 2009 included a favorable patent litigation settlement and contractual payments from Takeda associated with the conclusion of the TAP joint venture.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters